The field of oncology has seen transformative progress with the advent of radioligand therapies (RLTs), a class of precision medicine that uses radioactive isotopes to target and destroy cancer cells. Within the domain of neuroendocrine tumors (NETs), these therapies are making significant strides, moving from traditional beta-emitter radioligands to cutting-edge alpha-emitter...
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian